semaglutide bmi 25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Long-term weight loss effects of

A few minutes of light exposure during a draw is negligible

doi: 10.1038/ncomms2199 90 TarabolettiGDAscenzoSBorsottiPGiavazziRPavanADoloV

Health Care Professionals The current prescribing information for the GLP-1 RAs approved to treat patients with obesity or overweight contains information about the risk of suicidal thoughts and actions

Funding This work is supported by Eli Lilly and Company

PlexusDx serves all 50 states and accepts patients regardless of insurance status, offering compounded tirzepatide injections prepared by licensed 503A compounding pharmacies under strict pharmaceutical standards

Treatment can: Support significant, sustained weight reduction Lower the risk of heart disease, stroke, and some cancers Improve mobility and make physical activity easier Reduce high blood pressure Improve sleep quality Help manage type 2 diabetes when present Reduce the need for invasive procedures like bariatric surgery Improve blood sugar control and metabolic health Provide both injection and tablet options for flexibility Allow for daily or weekly dosing depending on the program Be used safely for long-term weight management Risks & Side Effects Serious complications from semaglutide are rare, but side effects are possible